Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 184,554 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension

NCT00332072
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

NCT04093895
View directory record Official record
Conditions
Periodontitis
Interventions
PerioSept(r)
Drug
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

NCT00855595
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Birmingham, Alabama • Denver, Colorado • West Palm Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 18, 2026, 5:31 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

NCT02485639
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

NCT00166439
View directory record Official record
Conditions
Lymphoma
Interventions
Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Results available

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

NCT00819039
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Ondansetron
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 18, 2026, 5:31 AM EDT
Withdrawn Not applicable Interventional

A Strategy to Improve Implementation of LTVV for Patients w/ ARDS

NCT03051139
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Multi-component LTVV implementation strategy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

A Study of SEA-CD40 Given With Other Drugs in Cancers

NCT04993677
View directory record Official record
Conditions
Melanoma, Carcinoma, Non-Small- Cell Lung
Interventions
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CET/PT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 18, 2026, 5:31 AM EDT
Recruiting Not applicable Interventional

Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

NCT06088277
View directory record Official record
Conditions
HIV Infections
Interventions
TM HIV, TM HL
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 18, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00066677
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
rhuMAB-VEGF, docetaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 18, 2026, 5:31 AM EDT
Recruiting No phase listed Observational

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

NCT06397677
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Research Testing Performed (Laboratory), Information Collected as Standard of Care, Research Testing Performed
Genetic · Diagnostic Test · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

NCT00221975
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex, Lamotrigine, Lithium
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 18, 2026, 5:31 AM EDT
Terminated Not applicable Interventional Results available

Functional Rehabilitation for Older Patients With Schizophrenia

NCT00712075
View directory record Official record
Conditions
Schizophrenia, Aging
Interventions
CBSST+PDA, Cognitive Behavioral Social Skills Training, PDA-only
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
45 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 18, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spirituality/Religiosity in Patients and Caregivers

NCT00634257
View directory record Official record
Conditions
Advanced Cancer, Solid Tumors
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Multicenter, Open-label, Safety and Tolerability Study

NCT01649557
View directory record Official record
Conditions
Schizophrenia
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 18, 2026, 5:31 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Biomarkers for Muscle Function and Aging in Chronic HIV Infection

NCT03011957
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 18, 2026, 5:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance

NCT02043457
View directory record Official record
Conditions
Obesity
Interventions
phenotyping
Other
Lead sponsor
University of Michigan
Other
Eligibility
15 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

A Study of LY3471851 in Participants With Psoriasis

NCT04119557
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, LY3471851
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Encinitas, California • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 18, 2026, 5:31 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Protandim and the Metabolic Syndrome

NCT01125501
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Protandim
Dietary Supplement
Lead sponsor
SomaLogic, Inc.
Industry
Eligibility
40 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 18, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional

Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy

NCT06492512
View directory record Official record
Conditions
Iron-deficiency Anemia (IDA), Pregnancy
Interventions
daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill, alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

NCT01055912
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
25
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 18, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

NCT05174312
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 18, 2026, 5:31 AM EDT